16252-90-7

Basic information

• Product Name: 2-Amino-2-methylpropanamide
• Synonyms: 2-Amino-2-methylpropanamide;2-methylalaninamide(SALTDATA: HCl);2-Amino-2-methylpropionicmide hydrochloride
• CAS NO: 16252-90-7
• Molecular Formula: C₄H₁₀N₂O
• Molecular Weight: 102.135
• Mol File: 16252-90-7.mol

Chemical Properties

• Melting Point: 260 °C
• Boiling Point: 234.7 °C at 760 mmHg
• Flash Point: 95.7 °C
• Appearance: /
• Density: 1.03 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: Methanol (Sparingly)
• PKA: 15.99±0.50(Predicted)
• CAS DataBase Reference: 2-Amino-2-methylpropanamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-2-methylpropanamide(16252-90-7)
• EPA Substance Registry System: 2-Amino-2-methylpropanamide(16252-90-7)

Safety Data

• Hazardous Substances Data: 16252-90-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-2-methylpropanamide is used as a building block for the synthesis of various pharmaceutical compounds. Its unique structure allows it to be incorporated into a wide range of molecules, making it a valuable component in drug design and development.
Used in HIV Inactivators:
2-Amino-2-methylpropanamide is used as a key component in the synthesis of probing mercaptobenzamides, which are known for their HIV inactivating properties. These compounds work by targeting the nucleocapsid protein 7 (NCp7) of the HIV virus, disrupting its function and effectively inactivating the virus. This application highlights the potential of 2-amino-2-methylpropanamide in the development of novel antiviral therapies.
Used in Synthesis of Other Compounds:
Due to its versatile structure, 2-amino-2-methylpropanamide is also used as a starting material or intermediate in the synthesis of various other organic compounds. Its reactivity and functional group compatibility make it a valuable asset in the synthesis of a wide range of molecules, including those with potential applications in various industries such as agriculture, materials science, and chemical manufacturing.

Upstream product

• 13257-67-5 2-amino-2-methylpropionic acid methyl ester 
• 19355-69-2 2-amino-2-cyanopropane 
• 16248-81-0 (1-cyano-1-methyl-ethyl)-phosphorimidic acid trichloride 
• 16256-14-7 2-amino-2-methyl-thiopropanamide 
• 50846-36-1 2-amino-2-methylpropanenitrile monohydrochloride 
• 17704-74-4 2-Amino-2-methyl-propionamide hydrochloride 
• 62-57-7 2-Aminoisobutyric acid 
• 15030-72-5 Z-Aib-OH 
• 73470-46-9 tert-butyl (1-amino-2-methyl-1-oxopropan-2-yl)carbamate 
• 81587-18-0 benzyl N-(2-amino-1,1-dimethyl-2-oxo-ethyl)carbamate 

Downstream Products

• 77-71-4 5,5-dimethyl-imidazolidine-2,4-dione 
• 62-57-7 2-Aminoisobutyric acid 
• 166538-23-4 α-(4-nitro-benzoylamino)-isobutyric acid amide 
• 666843-72-7 2-methyl-2-(2-nitrobenzenesulfonylamino)propionamide 
• 1610955-38-8 2-methyl-2-(2-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenoxy)acetamido)propanamide 

Relevant articles and documents

DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS

The present disclosure is concerned with dipeptide analogs that are capable of inhibiting TGF-β and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, methods for immunotherapy, and methods of treating fibroti

4-Isopropyl-6-methoxyphenyl glucitol compound

A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided. Specifically, a 4-isopropyl-6-methoxyphenyl glucitol compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof, is provided:

4-ISOPROPYL-6-METHOXYPHENYL GLUCITOL COMPOUND

A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided. Specifically, a 4-isopropyl-6-methoxyphenyl glucitol compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof, is provided:

PYRIDINE DERIVATIVES AS SODIUM CHANNEL BLOCKERS

Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein; each of R1 to R4 is independently selected from hydrogen and C1-4 alkyl, and each of rings A and B independently is optionally further substi

Methods and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS

The present invention provides nitrogen-containing fused-ring derivatives represented by the following general formula, or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications or obesity, in the formula R 1 represent H, an optionally substituted alkyl group, an alkenyl group, etc.; R 2 represent H, a halogen atom or an alkyl group; R 3 and R 4 represent H, OH, a halogen atom, an optionally substituted alkyl group, etc. ; Y represents CH or N; Q represents alkylene, alkenylene, etc.; ring A represents an aryl group or a heteroaryl group; G represents a group represented by the following general formula (G-1)or(G-2) (in which E 1 represents H, F or OH; and E 2 represents H, F, a methyl group, etc.), and pharmaceutical compositions comprising the same, and pharmaceutical uses thereof.

PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF

The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents a single bond, a C1-6 alkylene group etc. ; Z represents CO or SO2; R4 and R5 represent H, an optionally substituted C1-6 alkyl group etc.; and R3, R6 and R7 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF

The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C1-6 alkylene group etc.; Z represents -RB, -CORC etc. in which RB represents an optionally substituted C1-6 alkyl group etc.; and RC represents an optionally substituted C1-6 alkyl group etc.,; R4 represents H, an optionally substituted C1-6 alkyl group etc.; and R3, R5 and R6 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity, and a disease associated with the increase of blood galactose level such as galactosemia, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

Substituted 2-aminoacetamides and the use thereof

This invention is related to substituted 2-aminoacetamides represented by formula (II): or a pharmaceutically acceptable salt or prodrug thereof, wherein the substituents are defined herein. The invention also is directed to the use of substituted 2-amino

Substituent effect on acidity of substituted 2-(4-nitrobenzoylamino)alkanamidesin methanol-dimethyl sulfoxide mixtures

The dissociation constants of substituted 2-(4-nitrobenzoylamino)alkanamides, N-[2-(4-nitrobenzoylamino)aikanoyl]pyrrolidines, and N-alkyl-4-nitrobenzamides have been measured spectrophotometrically in 60 and 80% v/v DMSO. The pKA values of these N-acids are discussed from the point of view of substituents at the acetamide a-carbon atom.